In conjunction with the funding, Daniel Wagner, CI managing director of investments, will join SBI’s board of directors.
Led by president, chief executive officer and co-founder Paul Hallenbeck, Ph.D., the company advances a novel drug discovery platform that utilizes unstructured, synthetically produced peptides to generate “Synbodies” (synthetic antibodies). Its patent-pending technology, which has a broad range of potential therapeutic application areas including oncology, cardiovascular, central nervous system, diabetes and infectious disease, has been developed at Arizona State University (ASU) and supported with over $10m in funding to date.
SBI’s co-founders also include:
- Kevin Burroughs, Ph.D., vice president of research and development;
- Stephen Johnston, Ph.D., member of the scientific team; and
- Chris Diehnelt, Ph.D., member of the scientific team;